Metsera (NASDAQ:MTSR) Trading Up 5.7% - Here's What Happened

Metsera, Inc. (NASDAQ:MTSR - Get Free Report)'s share price was up 5.7% during mid-day trading on Monday . The stock traded as high as $19.58 and last traded at $19.58. Approximately 143,934 shares traded hands during trading, a decline of 83% from the average daily volume of 868,986 shares. The stock had previously closed at $18.53.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on MTSR shares. Cantor Fitzgerald assumed coverage on Metsera in a report on Tuesday, February 25th. They set an "overweight" rating for the company. Guggenheim assumed coverage on Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 target price on the stock. Bank of America initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 price target for the company. Finally, Evercore ISI assumed coverage on Metsera in a report on Tuesday, February 25th. They set an "outperform" rating on the stock.

Metsera Stock Up 5.5 %

The company has a fifty day moving average of $23.81.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.